An interventional study of inulin in Metabolic Syndrome, Healthy Participants and Metabolically Healthy Obesity, sponsored by Ball State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Ball State University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 578 studies in Metabolic Syndrome with a site in United States — 62 open to participants now, 84 under way, 3 of them phase 3. Metabolic Syndrome · United States.
Among the 578 studies in Metabolic Syndrome with a site in United States, this one is the 393rd largest by planned enrollment of the 490 interventional ones that give a count, is one of 18 that started in 2025, is one of 345 with no phase, reaches primary completion later than 18 of the 82 other live ones, and was the 553rd registered.
2,120 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →62 of the 578 studies in Metabolic Syndrome with a site in United States are open now. Recruiting first, the newest first:
Arizona State University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
Northwell Health · Sites in United States
Ages 21–75
Longevity Metrics, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
University of Virginia · Sites in United States
Ages 6–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
578 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 68 · Phase 3 20 · Phase 4 44
First in 1982; this study’s year is marked. 18 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 48 across the 490 interventional studies, 141 across the 86 observational. Of the 443 that completed or were terminated, 136 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 578 have an industry lead sponsor. The 10 most frequent:
Ball State University is the lead sponsor of 13 studies on the registry; 9 are open to participants now.
Ball State University has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
28 of the studies in Metabolic Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07625332Phase 3Northwell HealthPilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) | 2027-08 |
| NCT07095426Ball State UniversityImpact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes | 2026-11 |
| NCT04974554Medical University of South CarolinaFIT Families Multicomponent Obesity Intervention for African American Adolescents | 2026-11-30 |
| NCT05943626University of UtahCircadian Intervention to Improve Cardiometabolic Health | 2026-12 |
| NCT05654142University of Illinois at ChicagoThe PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older | 2026-12-31 |
Add all 28 to your calendar (.ics) → With an account.
Among the 578 studies in Metabolic Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Based on prior research, the investigators are interested in whether an intervention targeting gut health (supplemental fiber for 9 weeks total) will improve vascular health in individuals with obesity. Additionally, the investigators are interested in if this response differs based on whether individuals with obesity have very few heart disease risk factors or several heart disease risk factors.
The investigators will recruit individuals with obesity (body mass index ≥30 kg/m2) from Ball State University Campus and the surrounding community. Participants will be grouped as "metabolically healthy" (0-1 metabolic syndrome risk factors) or "metabolically unhealthy" (≥2 metabolic syndrome risk factors) Participants will be asked to consume inulin for 9 weeks total. Participants will consume 6g of inulin per day during week 1 as a run-in period. The following 8 weeks participants will consume 12g of inulin per day.
Participants will be asked to report for in-lab assessments/visits before the study begins (baseline), halfway through the intervention which starts following the 1-week run-in period (5 weeks), and at the conclusion of the intervention (9 weeks). At all of these assessments, participants will arrive in the morning (roughly 6-10 AM) having fasted for \~10 hours. We will then collect a blood sample, followed by several vascular measurements including flow-mediated dilation, pulse wave analysis, pulse wave velocity, and an electrocardiogram. Body weight and composition will also be assessed using a bioimpedance scale at each visit. Upon completion of each in-lab visit, participants will be asked to wear an ambulatory blood pressure monitoring device for 24 hours and will complete a 3-day food record. Dual-energy X-ray absorptiometry scans will be used to assess body composition at baseline and final study visits. Participants will provide a stool sample collected at home following baseline and final study visits as an optional procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will consume 6g of pre-portioned powdered inulin from chicory root daily for one week followed by 12g daily for eight weeks. Participants will fully dissolve it into a habitual cool or room temperature beverage to drink around the same time each day.
Dietary Supplement: inulin
6g inulin from chicory root per day for one week and 12g inulin per day for eight weeks dissolved into cool or room temperature liquid
Serum Soluble Cluster of Differentiation 14 (sCD14)
The investigators will measure fasting sCD14 at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Serum Lipopolysaccharide Binding Protein (LBP)
The investigators will measure fasting LBP at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Serum C-Reactive Protein (CRP)
The investigators will measure fasting CRP at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Heart Rate Variability (HRV)
The investigators will measure HRV at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Flow-Mediated Dilation (FMD)
The investigators will measure FMD at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Pulse Wave Velocity (PWV)
The investigators will measure PWV at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Aortic Aumentation
The investigators will measure aortic augmentation at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Augmentation Index (AIx)
The investigators will measure AIx at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Blood Pressure
The investigators will measure peripheral, central, and ambulatory blood pressure at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Glucose
The investigators will measure fasting glucose at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
High-Density Lipoprotein Cholesterol (HDL-C)
The investigators will measure fasting HDL-C at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Triglycerides
The investigators will measure fasting triglycerides at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Digestive Symptoms
The investigators will measure digestive symptoms at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Body Composition
The investigators will measure body composition using bioelectrical impedance and waist circumference at each visit, and dual-energy X-ray absorptiometry at the baseline and final visits. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Time frame: Through study completion, up to 1.5 years.
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 18 months is close to that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inulin
Ball State University